ProCE Banner Activity

Long-term Follow-up of Olaparib Maintenance Monotherapy in Platinum-Sensitive Serous Ovarian Cancer

Slideset Download
Conference Coverage
5-year follow-up of Study 19 to determine if olaparib maintenance monotherapy maintained a survival advantage over placebo in patients with BRCA-mutated platinum-sensitive ovarian cancer.

Released: June 08, 2016

Expiration: June 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals